Taiwan Liposome Company (TLC)
2F, 3 Yuanqu Street
Nankang
Taipei
115
Tel: 886-2-2655-7377
Fax: 886-2-2655-7366
Website: http://www.tlcbio.com/
Email: info@tlcbio.com
About Taiwan Liposome Company (TLC)
Taiwan Liposome Company (TLC) is a biopharmaceutical company focused on the research, development and commercialization of innovative pharmaceutical products based on its proprietary drug delivery technologies. Our strengths lie in lipid-based formulation and scale-up for parenteral drugs using micelles and nanoparticles to optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs.YEAR FOUNDED:
1997
LEADERSHIP:
Founder and CEO: Keelung Hong
CFO: Nicole Lin
JOBS:
Please click here for TLC job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW TLC:
Tweets by TLC
69 articles about Taiwan Liposome Company (TLC)
-
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
6/13/2022
Endo International plc announced that its subsidiary Endo Ventures Limited has executed an agreement with Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product.
-
TLC Announces TLC599 Agreement with EndoOne of the largest deals seen in Taiwan’s biotech sector
6/13/2022
TLC BioSciences announced that it has entered a commercialization agreement with Endo International plc for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain.
-
TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
3/7/2022
TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy.
-
TLC Reports Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the second quarter ended June 30, 2021 and provided a business update.
-
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India
5/26/2021
TLC and Zydus Healthcare Limited announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ in India.
-
TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India
5/25/2021
TLC announced that the Central Drugs Standard Control Organization of India has approved the New Drug Application of Amphotericin B Liposome for Injection 50mg for immediate importation per approved usage and indication, to aid in the country’s emergency of acute liposomal amphotericin B shortage.
-
InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19
5/23/2021
InspirMed Inc., a subsidiary of TLC that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine Congress.
-
TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years RunningPraised as benchmark for small and medium-sized enterprises
5/3/2021
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that it once again ranks in the Top 5% in Corporate Governance Evaluation amongst all Taiwan Stock Exchange Corporation and Taipei Exchange listed companies.
-
InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress
4/26/2021
InspirMed Inc. announced that a late-breaking abstract describing the potential advantages of ISPM21 and ISPM19 has been accepted by the scientific committee for poster presentation at the 23rd International Society for Aerosols in Medicine Congress.
-
TLC to Present at Upcoming Virtual Investor Conferences - Mar 02, 2021
3/2/2021
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that the Company’s management team will be presenting at the following virtual investor conferences:
-
TLC Reports Fiscal Year End 2020 Financial Results and Provides Business Update
2/5/2021
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the fiscal year ended December 31, 2020 and provided a business update.
-
TLC Announces Completion of US$15 Million Financing for Subsidiary InspirMed Inc.
1/4/2021
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that its subsidiary, InspirMed Inc., has completed a round of financing, raising US$15 million in cash from strategic investors in exchange for subsidiary equity.
-
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses
12/28/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that patient enrollment of EXCELLENCE, the Phase III pivotal clinical trial for TLC599 in patients with osteoarthritis knee pain, has been completed.
-
TLC Provides Corporate Update at Investor Conference - Dec 18, 2020
12/18/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, held a virtual investor conference earlier under the invitation of KGI Securities, and provided an update on the company’s pipeline as well as corporate strategy for the year ahead.
-
TLC Reports Third Quarter 2020 Financial Results and Provides Business Update
10/28/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the third quarter ending September 30, 2020, and provided a business update.
-
TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer
10/21/2020
TLC, a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced the appointment of Thomas H. Bliss, Jr., MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development.
-
TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)
10/14/2020
TLC announced that the first subject has been enrolled in the Phase I clinical trial of TLC19 for treatment or prophylaxis of Coronavirus disease 2019.
-
TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19Dual government support in streamlined development of anti-COVID-19 therapy
10/7/2020
TLC announced the receipt of ethical and scientific approval from the Bellberry Human Research Ethics Committee in Australia for the Company’s Phase I clinical trial of TLC19 Hydroxychloroquine Liposome Inhalation Suspension for Coronavirus disease 2019.
-
TLC to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
9/21/2020
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 23, 2020 at 9:10am ET.
-
TLC to Present at Cantor Virtual Global Healthcare Conference - Sep 11, 2020
9/11/2020
TLC announced that George Yeh, President of TLC, will be discussing recent activities regarding the company in a fireside chat with Kristen Kluska, Research Analyst, at Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:00am ET.